Claritin, Linens Make Strange Bedfellows But Licensing Revenue For Merck
This article was originally published in The Tan Sheet
Executive Summary
Merck has a strategy for squeezing more juice out of an OTC brand in an increasingly competitive market segment: out-licensing to non-drug products
You may also be interested in...
Perrigo Gains Pole Position In Private-Label Allegra Race
Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug
Claritin 12-Hour Takes Aim At Shorter-Duration Allergy Drugs
Schering-Plough extends the Claritin line into the 12-hour allergy relief niche to go after first-generation antihistamines with shorter durations
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC